A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Markus Borner, A. Roth, Damien Dietrich et al.|Annals of Oncology|2005

Cited by 103